The man who inspired the multiple award-winning movie “Jerry Maguire” meets the pioneering stem cell scientist who is ...

PhenQ, the strongest appetite suppressant over the counter (OTC), has officially launched in the United States and ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Erdem Hospital in Istanbul has announced the launch of a new pre-operative education program tailored specifically for ...

As a result, shareholders were not asked to approve the unallocated entitlements under the Company’s long-term incentive plan at the AGSM. For full voting details, please see the report of voting ...

The agreement, signed during CPHI China 2025, represents a high-level partnership between two influential players in their ...

CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Food and nutrition experts from around the world will gather in Nashville, Tenn., October 11-14, for the Academy of Nutrition and Dietetics' 2025 Food & ...

The gross proceeds from the Offering are approximately $19 million, before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds from the ...

PWR reinforces Jupiter's strategy of monetizing its proprietary science across both pharmaceutical and consumer verticals. The supplement joins GLO in the broader Nugevia ™ rollout, which the Company ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced eight abstracts from its novel clinical development programs, including oral presentations featuring its lead investigational drug ...

The Company expects additional tranches of the Offering to close on or before July 15, 2025.

Pyxis Oncology is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4).